Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03538262 · ClinicalTrials.gov registry record
Assessing Tele-Health Outcomes in Multiyear Extensions of PD Trials
A clinical trial, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 226
- Enrollment target
NCT03538262: Completed study, sponsored by Massachusetts General Hospital.
NCT03538262 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 226 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03538262 has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 226 participants
- Enrollment target
Study Summary
An observational study to characterize and compare long-term clinical outcomes data collected remotely through periodic tele-visits, interactive smartphone app sessions, and web-based surveys in individuals with Parkinson's Disease (PD) who have completed the interventional phases of the STEADY-PD3 and SURE-PD3 clinical trials.
Primary Outcome
Participants will be asked to complete (from home or other preferred environment) an hour-long Tele-visit that includes the Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS), comprising MDS-UPDRS part 1a and (modified) part 3, as well as completion or confirmation of patient-reported component parts 1b and 2. The MDS-UPDRS is assessed on a 5-point Likert scale ranging from 0 to 4 where higher scores imply worse features. Parts I-III contain 59 total questions (13 in
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 226 participants |
| Start Date | 2018-10-01 |
| Est. Completion | 2022-03-21 |
What the finished NCT03538262 record still lists
NCT03538262 is an observational study that tracks outcomes without assigning an intervention. The registered 226 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT03538262 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03538262 about?
NCT03538262 is a clinical study titled "Assessing Tele-Health Outcomes in Multiyear Extensions of PD Trials". An observational study to characterize and compare long-term clinical outcomes data collected remotely through periodic tele-visits, interactive smartphone app sessions, and web-based surveys in individuals with Parkinson's Disease (PD) who have completed the interventional phases of the STEADY-PD3 ...
What is the current status of trial NCT03538262?
This trial is currently completed. The enrollment target is 226 participants. The study started on 2018-10-01. Estimated completion is 2022-03-21.
Who is sponsoring clinical trial NCT03538262?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04419272 · 226 participants · Phase 4
Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits
- NCT05449002 · 226 participants · NA
Digital Single Session Intervention for Youth Mental Health
- NCT05488054 · 226 participants · NA
Muscle O2 Saturation and Hemoglobin Levels During Rehabilitation From Arthroscopic Surgery
- NCT05924477 · 226 participants · NA
Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI